Cargando…

Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study

BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fei, Liu, Fan, Lu, Jingchao, Yang, Xiuchun, Xiao, Bing, Jin, Yaqiong, Zhang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960150/
https://www.ncbi.nlm.nih.gov/pubmed/29776437
http://dx.doi.org/10.1186/s40001-018-0320-2
_version_ 1783324535796269056
author Chen, Fei
Liu, Fan
Lu, Jingchao
Yang, Xiuchun
Xiao, Bing
Jin, Yaqiong
Zhang, Jie
author_facet Chen, Fei
Liu, Fan
Lu, Jingchao
Yang, Xiuchun
Xiao, Bing
Jin, Yaqiong
Zhang, Jie
author_sort Chen, Fei
collection PubMed
description BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction. METHODS: Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial. The development of CIN was occurrence at the 48 or 72 h after the procedure. The changes of serum creatinine (SCr), eGFR, and Cys-C within 72 h after the procedure were measured and compared. In vivo contrast medium (CM)-induced acute kidney injury (AKI) animal model was established, and CoQ10 plus TMZ was orally administrated to evaluate its renal protective effect. RESULTS: 150 patients with renal insufficiency were enrolled finally. CIN occurred in 21 (14.00%) of the 150 patients. 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01). No cardiac death occurred in this study. No side effects were observed after administration of CoQ10 and TMZ. In vivo test demonstrated that CoQ10 and TMZ could significantly reduce the concentration of blood urea nitrogen (BUN) and SCR induced by CM i.v. injection, as well as tubular pathological injuries. Meanwhile, CoQ10 and TMZ could significantly reduce the oxidation stress in kidneys from CM-AKI animals. CONCLUSION: CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization, and their effect may be due to its strong anti-oxidation effect.
format Online
Article
Text
id pubmed-5960150
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59601502018-05-24 Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study Chen, Fei Liu, Fan Lu, Jingchao Yang, Xiuchun Xiao, Bing Jin, Yaqiong Zhang, Jie Eur J Med Res Research BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction. METHODS: Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial. The development of CIN was occurrence at the 48 or 72 h after the procedure. The changes of serum creatinine (SCr), eGFR, and Cys-C within 72 h after the procedure were measured and compared. In vivo contrast medium (CM)-induced acute kidney injury (AKI) animal model was established, and CoQ10 plus TMZ was orally administrated to evaluate its renal protective effect. RESULTS: 150 patients with renal insufficiency were enrolled finally. CIN occurred in 21 (14.00%) of the 150 patients. 72 h after the procedure, the incidence of CIN was significantly lower in CoQ10 plus TMZ group compared with control group (6.67 vs. 21.3%, p = 0.01). No cardiac death occurred in this study. No side effects were observed after administration of CoQ10 and TMZ. In vivo test demonstrated that CoQ10 and TMZ could significantly reduce the concentration of blood urea nitrogen (BUN) and SCR induced by CM i.v. injection, as well as tubular pathological injuries. Meanwhile, CoQ10 and TMZ could significantly reduce the oxidation stress in kidneys from CM-AKI animals. CONCLUSION: CoQ10 plus TMZ could decrease the incidence of CIN in patients with renal insufficiency undergoing elective cardiac catheterization, and their effect may be due to its strong anti-oxidation effect. BioMed Central 2018-05-18 /pmc/articles/PMC5960150/ /pubmed/29776437 http://dx.doi.org/10.1186/s40001-018-0320-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chen, Fei
Liu, Fan
Lu, Jingchao
Yang, Xiuchun
Xiao, Bing
Jin, Yaqiong
Zhang, Jie
Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title_full Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title_fullStr Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title_full_unstemmed Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title_short Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
title_sort coenzyme q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960150/
https://www.ncbi.nlm.nih.gov/pubmed/29776437
http://dx.doi.org/10.1186/s40001-018-0320-2
work_keys_str_mv AT chenfei coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT liufan coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT lujingchao coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT yangxiuchun coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT xiaobing coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT jinyaqiong coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy
AT zhangjie coenzymeq10combinedwithtrimetazidineinthepreventionofcontrastinducednephropathyinpatientswithcoronaryheartdiseasecomplicatedwithrenaldysfunctionundergoingelectivecardiaccatheterizationarandomizedcontrolstudyandinvivostudy